Biopharma Business

Tag "ACS"

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment ofcardiovascular and

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here